FDAsafety guidance66% confidence
FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Extrovis; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA207549. Sponsor: AMNEAL. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: METHYLPREDNISOLONE SODIUM SUCCINATE.
Supporting Context
- Therapeutic area
- General Medicine · Injectable
- Sub-indication
- General
Related signal: FDA Grants Approval for Sodium Acetate ANDA220274 by Extrovis